Blood‐based biomarker for identifying post‐mortem confirmed Cerebral Amyloid Angiopathy

Blood-based biomarkers capable of identifying CAA could play an important role in improving treatment outcomes by highlighting ARIA risk prior to treatment initiation. We found that plasma proteins related to inflammation, blood brain barrier dysfunction and cytoskeletal stability were significantly changed in participants with confirmed CAA. Further work will be required to replicate these findings in an independent dataset.